Table 2 Association between IL-6, IL-8 and sPD-L1 at baseline and clinical outcome after ICI
Biomarker | NSCLC stage (n) | Treatment | Direction at baseline | Association with clinical outcome | Ref | |||
|---|---|---|---|---|---|---|---|---|
Response | PFS | OS | ||||||
Cytokine | IL-6 | III-IV (n = 103) | αPD-1, αPD-L1, αPD-1/chemo, αPD-L1/ chemo | ↑ | ↓ (p = 0.007) | ↓ (p = 0.003) | [25] | |
IV (n = 29) | αPD-1 | ↑ | ↓ (p < 0.001) | ↓ (p < 0.001) | [26] | |||
III-IV (n = 125) | αPD-1, αPD-L1 | ↑ | ↓ (p = 0.003) | ↓ (p < 0.001) | ↓ (p < 0.001) | [27] | ||
Advanced NSCLC (n = 40), HNSCC (n = 41) | αPD-1 | ↑ | ↓ (p = 0.035) | ↓ (p = 0.011) | [28] | |||
III-IV (n = 45) | αPD-1 | ↑ | ↓ (p = 0.018) | ↓ (p = 0.0142) | [29] | |||
IL-8 | IIIB/IV squamous (n = 108) | αPD-1 | ↑ | ↓ (p = 0.0051) | [30] | |||
IIIB/IV nonsquamous (n = 255) | ↑ | ↓ (p < 0.0001) | ||||||
IV (n = 29) | αPD-1 | ↑ | ↓ (p = 0.006) | ↓ (p = 0.030) | [26] | |||
IIIB-IV (n = 143) | αPD-1, αPD-L1, αPD-1/chemo | ↑ | ↓ (p < 0.05) | [31] | ||||
Soluble Factor | sPD-L1 | IV solid tumor (n = 128, 50 with NSCLC) | ICI, ICI/other | ↑ | ↓ (p = 0.013) | ↓ (p = 0.023) | ↓ (p = 0.005) | [32] |
IV or recurrent (n = 39) | αPD-1 | ↑ | ↓ (p = 0.0069) | ↓ (p = 0.032) | ↓ (p = 0.040) | [33] | ||
Metastatic (n = 51) | αPD-1 | Positive | ↓ (p = 0.004) | ↓ (p = 0.013) | [34] | |||
Lung cancer (n = 485, from 6 studies) | ICI | ↑ | ns | ↓ (p < 0.001) | ↓ (p < 0.001) | [35] | ||
I-II (n = 3), III-IV (n = 40) | αPD-1 | ↑ | ↓ (p = 0.018) | ↓ (p = 0.096) | [36] | |||